• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 3. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Research Brief on (1S)-1-(4-ethylphenyl)ethan-1-amine (CAS: 212968-67-7): Recent Advances and Applications

The compound (1S)-1-(4-ethylphenyl)ethan-1-amine (CAS: 212968-67-7) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and therapeutic interventions. This research brief synthesizes the latest findings on this chiral amine, focusing on its synthesis, biological activity, and emerging roles in medicinal chemistry. Recent studies highlight its utility as a key intermediate in the synthesis of bioactive molecules, particularly in the development of central nervous system (CNS) targeting agents.

Recent advancements in asymmetric synthesis have enabled more efficient production of (1S)-1-(4-ethylphenyl)ethan-1-amine with high enantiomeric purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel enzymatic resolution method achieving >99% ee, significantly improving upon previous synthetic routes. This breakthrough has important implications for scaling up production while maintaining the stereochemical integrity critical for pharmacological activity. The study also revealed that the (S)-enantiomer exhibits 3-5 fold greater receptor binding affinity compared to its (R)-counterpart in serotonin receptor assays.

Pharmacological investigations have identified (1S)-1-(4-ethylphenyl)ethan-1-amine as a promising scaffold for developing novel antidepressants and anxiolytics. In vitro studies using human monoamine transporters show selective inhibition of serotonin reuptake (SERT IC50 = 12.3 nM) with minimal effects on dopamine and norepinephrine transporters. This selectivity profile, combined with molecular modeling data published in ACS Chemical Neuroscience (2024), suggests the compound's potential for developing next-generation SSRIs with reduced side effects. Notably, the ethylphenyl moiety appears to confer improved blood-brain barrier penetration compared to simpler phenyl derivatives.

Emerging applications extend beyond CNS disorders, with recent patent filings (WO2023184567) disclosing derivatives of 212968-67-7 as potent inhibitors of lysine-specific demethylase 1 (LSD1) for cancer therapy. The chiral center proves crucial for target engagement, as demonstrated by crystallographic studies showing hydrogen bonding between the amine group and FAD cofactor in LSD1. These findings position (1S)-1-(4-ethylphenyl)ethan-1-amine as a versatile building block for both neurological and oncological drug discovery programs.

Ongoing clinical investigations (Phase I/II trials NCT05678922) are evaluating the safety and pharmacokinetics of a pro-drug formulation containing this amine moiety. Preliminary results indicate favorable oral bioavailability (F = 78%) and linear pharmacokinetics up to 300 mg doses. The compound's metabolic stability, attributed to the ethyl substitution pattern, addresses common limitations of similar aromatic amines, as detailed in a recent review in Drug Metabolism Reviews (2024). These properties make it particularly attractive for chronic administration regimens.

In conclusion, (1S)-1-(4-ethylphenyl)ethan-1-amine represents a chemically and biologically significant compound with expanding therapeutic potential. The convergence of improved synthetic methods, detailed mechanistic understanding, and promising clinical data suggests this chiral amine will continue to play an important role in pharmaceutical development. Future research directions likely include exploration of additional derivatives and combination therapies leveraging its unique pharmacophoric features.

• 98-84-0(α-Phenylethylamine)
• 147116-33-4(1-(4-Ethylphenyl)ethanamine hydrochloride)
• 3886-69-9((1R)-1-phenylethan-1-amine)
• 27298-98-2((S)-(?)-α,4-Dimethylbenzylamine)
• 4187-38-6((R)-4-Tolylethylamine)
• 618-36-0(1-phenylethan-1-amine)
• 138457-18-8((1S)-1-(3-methylphenyl)ethan-1-amine)
• 138457-19-9((1R)-1-(3-methylphenyl)ethan-1-amine)
• 292068-37-2((1R)-1-(4-ethylphenyl)ethan-1-amine)
• 2627-86-3((S)-alpha-phenylethylamine)